Ahmad A Tarhini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3924929/publications.pdf

Version: 2024-02-01

138 papers	8,322 citations	81900 39 h-index	54911 84 g-index
143 all docs	143 docs citations	143 times ranked	11570 citing authors

#	Article	IF	Citations
1	Adjuvant Pembrolizumab versus IFNÎ±2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discovery, 2022, 12, 644-653.	9.4	32
2	The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 95-104.	4.1	3
3	Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. , 2022, 10, e004310.		6
4	Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clinical Cancer Research, 2022, 28, 2131-2146.	7.0	36
5	Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. Journal of Translational Medicine, 2022, 20, .	4.4	5
6	Adjuvant Therapy of Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 73-84.	2.2	2
7	CTLA-4 blockade and interferon-Î± induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS ONE, 2021, 16, e0245287.	2.5	7
8	Early Cortisol and Inflammatory Responses to Parental Cancer and Their Impact on Functional Impairment in Youth. Journal of Clinical Medicine, 2021, 10, 576.	2.4	1
9	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 2021, 27, 301-309.	30.7	218
10	Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFNÎ± in melanoma. Translational Oncology, 2021, 14, 101014.	3.7	13
11	Neoadjuvant Pembrolizumab and High-Dose IFNÎ±-2b in Resectable Regionally Advanced Melanoma. Clinical Cancer Research, 2021, 27, 4195-4204.	7.0	18
12	A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanomaâ˜†. ESMO Open, 2021, 6, 100050.	4.5	14
13	Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. , 2021, 9, e002535.		13
14	Multidisciplinary Care of<scp>BRAF-Mutant</scp>Stage<scp>III</scp>Melanoma: A Physicians Perspective Review. Oncologist, 2021, 26, e1644-e1651.	3.7	5
15	Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. Future Oncology, 2021, 17, 2151-2167.	2.4	4
16	Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. Immunotherapy, 2021, 13, 1011-1029.	2.0	8
17	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. , 2021, 9, e003675.		24
18	Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. Journal of Clinical Oncology, 2020, 38, 567-575.	1.6	122

#	Article	IF	Citations
19	The current state of adjuvant therapy of melanoma. Lancet Oncology, The, 2020, 21, 1394-1395.	10.7	12
20	Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.. Journal of Clinical Oncology, 2020, 38, 60-60.	1.6	1
21	Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. Journal of Comparative Effectiveness Research, 2019, 8, 461-473.	1.4	16
22	Neoadjuvant therapy of locally/regionally advanced melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986695.	3.2	21
23	Uveal Melanoma: Metastases. , 2019, , 317-329.		0
24	The impact of CTLA-4 blockade and interferon-Î± on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients. OncoImmunology, 2019, 8, e1652538.	4.6	22
25	Multiple antigen-engineered DC vaccines with or without IFNÎ± to promote antitumor immunity in melanoma. , 2019, 7, 113.		31
26	Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. Immunotherapy, 2019, 11, 617-629.	2.0	29
27	Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma. Journal of Comparative Effectiveness Research, 2019, 8, 1349-1363.	1.4	5
28	Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. Immunotherapy, 2019, 11, 283-295.	2.0	24
29	Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study. Future Oncology, 2019, 15, 359-370.	2.4	11
30	E3611â€"A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-Î±2b in Advanced Melanoma. Clinical Cancer Research, 2019, 25, 524-532.	7.0	8
31	An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell, 2019, 35, 33-45.e6.	16.8	125
32	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. Oncologist, 2019, 24, 4-8.	3.7	7
33	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. Journal of Clinical Oncology, 2019, 37, 9503-9503.	1.6	34
34	United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-Î±2b for resected high-risk melanoma.. Journal of Clinical Oncology, 2019, 37, 9504-9504.	1.6	15
35	Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma. Melanoma Research, 2018, 28, 618-628.	1.2	23
36	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. Journal of Clinical Oncology, 2018, 36, 3450-3458.	1.6	55

#	Article	IF	Citations
37	Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. Journal of Translational Medicine, 2018, 16, 184.	4.4	36
38	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. Cancer Treatment Reviews, 2018, 71, 8-18.	7.7	58
39	NCI 8628: A randomized phase 2 study of zivâ€aflibercept and highâ€dose interleukin 2 or highâ€dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer, 2018, 124, 4332-4341.	4.1	15
40	Neoadjuvant ipilimumab (3Âmg/kg or 10Âmg/kg) and high dose IFN-Î±2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. , 2018, 6, 112.		50
41	Sequential treatment approaches inÂ the management of BRAF wild-type advanced melanoma: a costâ€“effectiveness analysis. Immunotherapy, 2018, 10, 1241-1252.	2.0	19
42	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
43	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. New England Journal of Medicine, 2018, 379, 722-730.	27.0	983
44	Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN-Î±2b in locally/regionally advanced melanoma.. Journal of Clinical Oncology, 2018, 36, 181-181.	1.6	8
45	Phase III Randomized Study of 4 Weeks of High-Dose Interferon-Î±-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Groupâ€“American College of Radiology Imaging Network Cancer Research Group (E1697). Journal of Clinical Oncology, 2017, 35, 885-892.	1.6	42
46	Adjuvant Therapy for Melanoma. Current Oncology Reports, 2017, 19, 36.	4.0	26
47	Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Management, 2017, 4, 13-37.	0.5	97
48	Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced nonâ€“small cell lung cancer. Cancer, 2017, 123, 2936-2944.	4.1	36
49	The use of immunotherapy in the treatment of melanoma. Journal of Hematology and Oncology, 2017, 10, 88.	17.0	89
50	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clinical Cancer Research, 2017, 23, 5034-5043.	7.0	34
51	A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOGâ€ACRIN Cancer Research Group (E2607). Cancer, 2017, 123, 2688-2697.	4.1	103
52	Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. Journal of Translational Medicine, 2017, 15, 39.	4.4	9
53	Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-Î±2b in patients with metastatic melanoma. Melanoma Research, 2017, 27, 342-350.	1.2	15
54	Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. OncoImmunology, 2017, 6, e1231291.	4.6	29

#	Article	IF	Citations
55	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 651-660.	3.8	5
56	High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. , 2017, 5, 74.		45
57	Comprehensive Reporting in Cost-Effectiveness Modeling. Journal of Clinical Oncology, 2017, 35, 3085-3086.	1.6	6
58	Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.. Journal of Clinical Oncology, 2017, 35, 9507-9507.	1.6	106
59	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 651-660.	3.8	7
60	Vaccine therapy + dasatinib for the treatment of patients with stage IIIBâ€“IV melanoma. Melanoma Management, 2016, 3, 251-254.	0.5	4
61	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, 2016, 13, 473-486.	27.6	831
62	Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). International Journal of Radiation Oncology Biology Physics, 2016, 95, 632-646.	0.8	132
63	Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. , 2016, 4, 38.		22
64	Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma.. Journal of Clinical Oncology, 2016, 34, 9585-9585.	1.6	5
65	Immunotherapy of Melanoma. Current Molecular Pharmacology, 2016, 9, 196-207.	1.5	9
66	Risk Reductions of Recurrence and Mortality in Melanoma Patients Using IFN-Î±. , 2016, , 49-63.		0
67	Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. Journal of Translational Medicine, 2015, 13, 319.	4.4	27
68	Baseline circulating IL-17 predicts toxicity while TGF-Î²1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. , 2015, 3, 39.		302
69	Neoadjuvant Therapy for Melanoma: A Promising Therapeutic Approach and an Ideal Platform in Drug Development. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e535-e542.	3.8	8
70	Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-Î± but Not Observation in Intermediate Risk Melanoma Patients. PLoS ONE, 2015, 10, e0132745.	2.5	9
71	Immune Checkpoint Blockade and Interferon-Î± in Melanoma. Seminars in Oncology, 2015, 42, 436-447.	2.2	34
72	Anticancer Cytokines: Biology and Clinical Effects of Interferon-Î±2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Seminars in Oncology, 2015, 42, 539-548.	2.2	179

#	Article	IF	Citations
73	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Groupâ€“American College of Radiology Imaging Network Cancer Research Group (E4697). Journal of Clinical Oncology, 2015, 33, 4066-4076.	1.6	101
74	High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. , 2014, 2, 26.		130
75	Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma. JAMA - Journal of the American Medical Association, 2014, 312, 1744.	7.4	312
76	Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Research, 2014, 24, 150-157.	1.2	12
77	A four-marker signature of TNF-RII, TGF-Î±, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. Journal of Translational Medicine, 2014, 12, 19.	4.4	42
78	Surviving with lung cancer: Medication-taking and oral targeted therapy. Geriatric Nursing, 2014, 35, S49-S56.	1.9	14
79	Melanoma Adjuvant Therapy. Hematology/Oncology Clinics of North America, 2014, 28, 471-489.	2.2	13
80	Abstract 2911: Immune related melanoma gene expression profile predicts neoadjuvant ipilimumab clinical benefit. , 2014, , .		1
81	Clustered genomic variants specific to patients who develop immune-related colitis after ipilimumab for prediction of toxicity.. Journal of Clinical Oncology, 2014, 32, 9024-9024.	1.6	1
82	Phase I study of rilotumumab (AMG 102), an HGF inhibitor, and erlotinib in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, e19065-e19065.	1.6	3
83	Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab. PLoS ONE, 2014, 9, e87705.	2.5	261
84	A unique gene expression signature in tumor positive or negative sentinel lymph nodes in patients with melanoma.. Journal of Clinical Oncology, 2014, 32, 9087-9087.	1.6	0
85	NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanomaâ€”Efficacy and biomarker study.. Journal of Clinical Oncology, 2014, 32, TPS9120-TPS9120.	1.6	0
86	Prognostic significance of sentinel lymph node biopsies (SLNB) in melanoma.. Journal of Clinical Oncology, 2014, 32, e20029-e20029.	1.6	0
87	Melanoma adjuvant therapy. Chinese Clinical Oncology, 2014, 3, 26.	1.2	6
88	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews Clinical Oncology, 2013, 10, 588-598.	27.6	177
89	Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clinics in Dermatology, 2013, 31, 237-250.	1.6	40
90	Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management. Scientifica, 2013, 2013, 1-19.	1.7	186

#	Article	IF	Citations
91	Tremelimumab: a review of development to date in solid tumors. Immunotherapy, 2013, 5, 215-229.	2.0	55
92	High-dose interleukin-2 (HD IL-2) in the treatment of advanced melanoma: The University of Pittsburgh experience.. Journal of Clinical Oncology, 2013, 31, 9075-9075.	1.6	2
93	Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608.. Journal of Clinical Oncology, 2013, 31, CRA9007-CRA9007.	1.6	8
94	Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608.. Journal of Clinical Oncology, 2013, 31, CRA9007-CRA9007.	1.6	23
95	Differential genomic profiles of tumor-involved and tumor-free sentinel lymph nodes in patients with melanoma.. Journal of Clinical Oncology, 2013, 31, 9043-9043.	1.6	0
96	Phase II study of low-dose peginterferon alfa-2b antiangiogenic therapy in patients with metastatic melanoma overexpressing basic fibroblast growth factor: An Eastern Cooperative Oncology Group study (E2602).. Journal of Clinical Oncology, 2013, 31, 9038-9038.	1.6	0
97	T-regulatory cell function analysis in locally/regionally advanced melanoma patients treated with ipilimumab.. Journal of Clinical Oncology, 2013, 31, 3041-3041.	1.6	0
98	Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. Anticancer Research, 2013, 33, 4475-81.	1.1	26
99	Adjuvant Therapy for Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 192-202.	2.0	47
100	Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma. Journal of Clinical Oncology, 2012, 30, 322-328.	1.6	131
101	How Much of a Good Thing? What Duration for Interferon Alfa-2b Adjuvant Therapy?. Journal of Clinical Oncology, 2012, 30, 3773-3776.	1.6	18
102	Safety and Immunogenicity of Vaccination With MART-1 (26â€“35, 27L), gp100 (209â€“217, 210M), and Tyrosinase (368â€“376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma. Journal of Immunotherapy, 2012, 35, 359-366.	2.4	53
103	Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-Î± or TLR-9 Agonist and GM-CSF With Peptide Vaccination. Journal of Immunotherapy, 2012, 35, 702-710.	2.4	63
104	IFN-Î± in the Treatment of Melanoma. Journal of Immunology, 2012, 189, 3789-3793.	0.8	112
105	Immunotherapy of cancer in 2012. Ca-A Cancer Journal for Clinicians, 2012, 62, 309-335.	329.8	379
106	Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview. , 2012, , 305-317.		1
107	Pilot evaluation of sulforaphane in melanoma patients with multiple atypical nevi: Tissue STAT1 and STAT3 as risk markers.. Journal of Clinical Oncology, 2012, 30, TPS8606-TPS8606.	1.6	0
108	Phase II study of the anti-ganglioside ÂGD3 mouse/human chimeric antibody KW2871 combined with high dose interferon-a2b in patients with metastatic melanoma.. Journal of Clinical Oncology, 2012, 30, 8547-8547.	1.6	0

#	Article	IF	Citations
109	A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607).. Journal of Clinical Oncology, 2012, 30, 8522-8522.	1.6	2
110	Association of high T-cell immune infiltrate and low hemorrhage in melanoma brain metastases (MBMs) with prolonged survival.. Journal of Clinical Oncology, 2012, 30, 8528-8528.	1.6	0
111	Prognostic significance of autoimmunity during treatment of melanoma with interferon. Seminars in Immunopathology, 2011, 33, 385-391.	6.1	143
112	Neoadjuvant therapy for highâ€risk bulky regional melanoma. Journal of Surgical Oncology, 2011, 104, 386-390.	1.7	22
113	Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin. Clinical Cancer Research, 2011, 17, 6574-6581.	7.0	77
114	A Phase I Study of Concurrent Chemotherapy (Paclitaxel and Carboplatin) and Thoracic Radiotherapy with Swallowed Manganese Superoxide Dismutase Plasmid Liposome Protection in Patients with Locally Advanced Stage III Non-Small-Cell Lung Cancer. Human Gene Therapy, 2011, 22, 336-342.	2.7	60
115	Adjuvant Therapy: Melanoma. Journal of Skin Cancer, 2011, 2011, 1-19.	1.2	13
116	CTLA-4 blockade: therapeutic potential in cancer treatments. OncoTargets and Therapy, 2010, 3, 15.	2.0	67
117	Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 601-613.	1.0	125
118	CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma. Oncology, 2010, 24, 1302, 1304.	0.5	7
119	Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. Expert Opinion on Drug Discovery, 2009, 4, 587-603.	5.0	6
120	Biomarkers of Therapeutic Response in Melanoma and Renal Cell Carcinoma: Potential Inroads to Improved Immunotherapy. Journal of Clinical Oncology, 2009, 27, 2583-2585.	1.6	24
121	Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694. Journal of Clinical Oncology, 2009, 27, 38-44.	1.6	105
122	A phase 2, randomized study of SBâ€485232, rhILâ€18, in patients with previously untreated metastatic melanoma. Cancer, 2009, 115, 859-868.	4.1	96
123	Clinical and Immunologic Basis of Interferon Therapy in Melanoma. Annals of the New York Academy of Sciences, 2009, 1182, 47-57.	3.8	36
124	Despite past disappointments, the future of melanoma therapy appears bright. Oncology, 2009, 23, 509, 515.	0.5	0
125	Practical guidelines for the management of interferonâ€Î±â€2b side effects in patients receiving adjuvant treatment for melanoma. Cancer, 2008, 112, 982-994.	4.1	116
126	Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer, 2008, 112, 1131-1138.	4.1	22

#	Article	IF	Citations
127	A phase 2 trial of sequential temozolomide chemotherapy followed by highâ€dose interleukin 2 immunotherapy for metastatic melanoma. Cancer, 2008, 113, 1632-1640.	4.1	22
128	Next Generation of Immunotherapy for Melanoma. Journal of Clinical Oncology, 2008, 26, 3445-3455.	1.6	215
129	Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opinion on Biological Therapy, 2008, 8, 1583-1593.	3.1	38
130	Oblimersen in the treatment of metastatic melanoma. Future Oncology, 2007, 3, 263-271.	2.4	32
131	Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Current Opinion in Molecular Therapeutics, 2007, 9, 505-14.	2.8	9
132	Cutaneous melanoma: available therapy for metastatic disease. Dermatologic Therapy, 2006, 19, 19-25.	1.7	121
133	Novel agents in development for the treatment of melanoma. Expert Opinion on Investigational Drugs, 2005, 14, 885-892.	4.1	13
134	Interleukin-2 for the treatment of melanoma. Current Opinion in Investigational Drugs, 2005, 6, 1234-9.	2.3	31
135	Management of brain metastases in patients with melanoma. Current Opinion in Oncology, 2004, 16, 161-166.	2.4	54
136	Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy. Journal of Clinical Oncology, 2002, 20, 3703-3718.	1.6	194
137	Cutaneous Melanoma: Therapeutic Approaches for Metastatic Disease. , 0, , 313-324.		0
138	Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. Molecular Carcinogenesis, 0, , .	2.7	8